Ann: Business Development Update, page-17

First 17 Last

Share
Profile

Follow
troutfisho

1,099 Posts.

199

24/07/18

12:12

Post #: 34534918
Share

Originally posted by Bluebush ↑

By my reckoning you're right kipp (Post #: 34528500). It's not a bad thing if current share and note holders maintain the faith and have supported the Co.

I have. I sold some across all my accounts to crystallise some losses, bought some back (mainly at a pip higher) and have exercised my rights. It sounds like I'm not the only clown.

Anyway, the opportunities are there (maybe). The latest presso was more professional than any so far, but there was a couple of things that sh*t me.

I really hated the reference to CBD (no not clyde, cannabidiol). As someone said "it is so 2017" everyone from busted-ass miners, bit-coiners and online porn sites jumped on the THC band wagon, it’s a case of the horse having already bolted. By the way, there may be an opportunity to increase the speed of action, but oro-mucosal will never be as quick as via the lungs and there are a million different methods that users (non-smokers) have available and if pain is the priority then sooner is better. So, I think that reference is very bollocksy.

So is the reference to oestradiol. That's the first time that Carter has published that data. I really hope that was NVDL research rather than something Carter has sanctioned time and money being spent on. Acrux (ACR) has a product Evamist (oestradiol transdermal spray) which has gone nowhere. Maybe it’s the link between HRT and breast cancer Stevo???

Anyway, that’s pure speculation on my part that Carters “scattergun” approach included investing dollars that he didn’t have on these two areas. (Oh, by the way Stevo in Australia it’s called a shotgun).

There seems to be increasing emphasis on David Phillips being the next “great white hope.” Seems he’s responsible for 50 “deals” and a bunch of M&A’s. I just hope that his repertoire isn’t as inflated as Carters employment by Pfizer. He does however seem to have more experience than the rest of the clowns.

I really hate to say this but Stewarts departure from this company, ostensibly under some very sad circumstances, does look somewhat curious.

NDF research target of 4c to 14c looks very ambitious.

The Clemastine fumarate graph is interesting. Sandoz have a generic of this product and by my interpretation of the graph there’s a real benefit that’s been evidenced. This is potentially a good product. Same can be said for the Ondansetron and Zolpi graphs which show great efficacy.

“5 years of explosive growth”- Qué (enter from left little Spanish dude from Faulty Towers)

BD is the new company wank-word. “Suda to invest BD into High Value US market.” Sure we are. “Deals done by F2F and B2B meetings.” FFS. “Suda to employ US based BD Specialist in Q1 FY2019.” Great so we are going to employ another dude (in US dollars). What happened to the other dude that we were advertising for, about 2 weeks before the BerlinFarmer SHTF?

Currently >15 JD/JV opportunities. OK??

Anticipated Milestones. Well I nearly had a heart attack. At some stage people should be held accountable for making ridiculous projections that are clearly aimed at getting money into the company and not about any chance of really occurring. But I guess if pollies can promise the world prior to an election and then deliver nothing then how’s this bollocks any different? Dodgey really and I for one have no faith in this table. (Sorry Marg)

Anyway, I’m still in. I think that at half a cent if you are buying in (new), then it might be good for a one or two bagger.

Of course, all this is worth nought if they only raise $4 MM because that will allow free cash of only 3 months!!!!

Expand

Blue- the little Spanish dude was Manuel!
SUD reminds me very much of Fawlty Towers-Lots of paddling and everything f.. up.
Agree that the preso is largely bulldust... again. But more professional bulldust this time.
I called the Stewart departure at the time and thought I was being harsh. Maybe not.

SUD Price at posting: 0.5¢ Sentiment: None Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

ATC

Altech launches CERENERGY prototype in Germany, with early tests proving positive

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

TON

Triton snaffles 588 square km gold-copper play in Mozambique

BM8

Battery Age Minerals launches field campaign at Austrian Bleiberg lead-zinc-germanium play

There are more pages in this discussion • 11 more messages in this thread...

First 17 Last

Add ALA (ASX) to my watchlist

(20min delay)
Last 16.0¢		Change 0.005(3.23%)		Mkt cap ! $168.2M

Open	High	Low	Value	Volume
15.5¢	16.0¢	15.5¢	$199.6K	1.266M

Buyers (Bids)

No.	Vol.	Price($)
6	279510	15.5¢

Sellers (Offers)

Price($)	Vol.	No.
16.5¢	832522	11

View Market Depth

No.	Vol.	Price($)
2	26603	0.160
6	279510	0.155
13	648025	0.150
9	270205	0.145
7	234046	0.140

Price($)	Vol.	No.
0.165	832522	11
0.170	1060860	12
0.175	994999	9
0.180	1194230	8
0.185	44396	5

Last trade - 11.47am 01/10/2024 (20 minute delay)

ALA (ASX) Chart

Ann: Business Development Update, page-17

Altech launches CERENERGY prototype in Germany, with early tests proving positive

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Triton snaffles 588 square km gold-copper play in Mozambique

Battery Age Minerals launches field campaign at Austrian Bleiberg lead-zinc-germanium play

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Business Development Update, page-17

Top Stories

Altech launches CERENERGY prototype in Germany, with early tests proving positive

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Triton snaffles 588 square km gold-copper play in Mozambique

Battery Age Minerals launches field campaign at Austrian Bleiberg lead-zinc-germanium play

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News